Fig. 4: Knockout of METTL14 suppresses oncogenic KrasG12D/+-induced myeloid disease in a cell-autonomous manner. | Cell Death & Differentiation

Fig. 4: Knockout of METTL14 suppresses oncogenic KrasG12D/+-induced myeloid disease in a cell-autonomous manner.

From: The m6A methyltransferase METTL14 promotes oncogenic Kras induced juvenile myelomonocytic leukemia through dysregulating autophagy

Fig. 4

Control, Kras, and Kras;M14-/- mice were sacrificed on day 1 of week seven for transplantation experiments. Lethally irradiated mice were transplanted with 2.5×105 BM cells from different groups of mice along with same number of competitor cells. Four weeks after transplantation, Mx1-Cre expression was induced by pI-pC injections. A Kaplan-Meier survival curves of different groups of recipient mice were plotted against days after transplantation. P values were determined by the Log-rank test. B Disease distribution patterns in recipient mice transplanted with Kras or Kras;M14-/- cells. We define the mice with a myeloid disease when donor-derived monocytes consist >20% of white blood cells in peripheral blood. Chi-square analysis was performed. C Total donor-derived cells and donor-derived T cells, B cells, myeloid cells, neutrophils and monocytes(CD45.2+) in different groups of recipients were evaluated regularly after transplantation. Of note, 4-week data were collected right before pI-pC injections. D Quantitative analysis of Thymus weight, spleen weight and Liver weight. E Quantitative analysis of donor-derived myeloid cells, monocytes and neutrophils in BM, SP and PB from moribund recipient mice. The results are presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page